TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name EGFR-TKI
Drug Type Small molecule
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 243
Ref_1
Pair Name (20S)-Protopanaxatriol, EGFR-TKI
Partner Name (20S)-Protopanaxatriol
Disease Info [ICD-11: 2C25.Z] Lung cancer Investigative
Biological Phenomena Induction-->Lipid accumulation
Gene Regulation Down-regulation Expression SCD hsa6319
Down-regulation Phosphorylation EGFR hsa1956
In Vitro Model HCC827 Lung adenocarcinoma Homo sapiens (Human) CVCL_2063
PC-9 Lung adenocarcinoma Homo sapiens (Human) CVCL_B260
NCI-H1975 Lung adenocarcinoma Homo sapiens (Human) CVCL_1511
HCC827-GR-high1 Lung adenocarcinoma Homo sapiens (Human) CVCL_S703
In Vivo Model Approximately 1×10⁷ H1975-luc cells were subcutaneously injected into the right hind limbs of mice.
Result Our findings uncover a link between lipid metabolic reprogramming and EGFR-TKI resistance, confirmed that combination target both EGFR and abnormal lipid metabolism maybe a promising therapy for EGFR-TKI resistance and highlighting the possibility of monitoring lipid accumulation in tumors for predicting drug resistance.
03. Reference
No. Title Href
1 Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. doi: 10.1186/s13046-019-1120-4. Click
It has been None visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP